Use of embolic protection devices during saphenous vein graft (SVG) interventions is associated with an increase in procedural complications without corresponding improvements in clinical outcomes for ...
PARIS, France—A new analysis of more than 10,000 patients likely slams the door on routinely using cerebral embolic protection for stroke prevention in patients with aortic stenosis undergoing TAVI.
SANTA CRUZ, Calif., Oct. 23, 2025 /PRNewswire/ -- Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient ...
Emboline’s new financing could help jumpstart the company into a clinical trial and launch of its embolic protection device used in connection with Transcatheter Aortic Valve Replacement. The Santa ...
WASHINGTON, DC — Are surrogate end points enough to recommend a treatment that seems safe but hasn't "worked" by clinical-trial standards, but many agree ought to work? A pair of catheter-delivered ...
United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...
There has been an increase in the need for embolization protection devices as the risk for stroke and other neurological damage from transcatheter aortic valve replacement (TAVR) procedures continues ...
A multicenter EPIC (FiberNet Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System had a 97.5 percent success rate when used in patients ...
WASHINGTON, DC — An embolic-protection device delivered percutaneously via the radial artery and used during transcatheter aortic-valve implantation (TAVI) in high-risk patients with aortic stenosis ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...
Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results